Active Ingredients: Azithromycin
Uncomplicated genital infections due to Chlamydia trachomatis; Chancroid 1 g as a single dose. Uncomplicated gonorrhoea 1 g or 2 g as a single dose, combined with ceftriaxone. As extended release suspension: 2 g as a single dose.
Prophylaxis of disseminated Mycobacterium avium complex MAC infections 1. IV Community-acquired pneumonia 500 mg as a single daily dose for at least 2 days followed by oral dose of 500 mg daily to complete 7-10 days.
Pelvic inflammatory disease 500 mg daily as a single dose for 1 or 2 days followed by oral dose of 250 mg daily to complete 7 days.
Oral Chancroid, Uncomplicated genital infections due to Chlamydia trachomatis Adult: 1 g as a single dose.
Oral Acute bacterial sinusitis Adult: As tab, cap or immediate release suspension: 500 mg once daily for 3 days.
Oral Respiratory tract infections, Skin and soft tissue infections Adult: As tab, cap, or immediate release suspension: 500 mg daily for 3 days.
Alternatively, 500 mg as single dose on day 1 followed by 250 mg daily on days 2-5. Oral Adult: 1 g or 2 g as a single dose, in combination with ceftriaxone. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.
Warnings Rare serious allergic reactions, including angioedema and anaphylaxis, have been reported rarely in patients on azithromycin therapy.
Despite initially successful symptomatic treatment of the allergic symptoms, when symptomatic therapy was discontinued, the allergic symptoms recurred soon thereafter in some patients without further azithromycin exposure.
These patients required prolonged periods of observation and symptomatic treatment.
The relationship of these episodes to the long tissue half-life of azithromycin and subsequent prolonged exposure to antigen is unknown at present. If an allergic reaction occurs, the drug should be discontinued and appropriate therapy should be instituted.
In the treatment of pneumonia, azithromycin has only been shown to be safe and effective in the treatment of community-acquired pneumonia of mild severity due to Streptococcus pneumoniae or Haemophilus influenzae in patients appropriate for outpatient oral therapy.